Pain

The NaV1.8 inhibitor showed a statistically significant change from baseline in lumbosacral radiculopathy pain, but it was the same as the reduction in the study’s placebo arm.

Vertex may win US FDA approval in January for the first novel pain drug in decades, after investing a lot of time and inventing new technology to unravel the science behind suzetrigine.

SiteOne will use its series C venture capital to complete Phase I and initiate Phase II studies for its NaV1.8 inhibitor STC-004 in acute and chronic pain, and to advance other early programs.